-
AbbVie Sues Genmab Over Alleged Trade Secret Misappropriation in ADC Development
•
US pharmaceutical giant AbbVie (NYSE: ABBV) has filed a lawsuit in the U.S. District Court for the Western District of Washington, D.C., naming Genmab A/S (NASDAQ: GMAB), Profound Bio US Co., ProfoundBio (Suzhou) Co., Ltd., and former AbbVie employees as defendants. The lawsuit alleges misappropriation of AbbVie’s trade secrets related…
-
FRα ADC Rina-S by Genmab Enters Late-Stage Clinical Trial Following ProfoundBio Acquisition
•
Genmab A/S (NASDAQ: GMAB) has initiated a Phase III clinical trial for its FRα ADC candidate, Rina-S, as registered on ClinicalTrials.gov on October 1, 2024. The trial aims to enroll 530 patients with platinum-resistant advanced ovarian cancer to compare Rina-S head-to-head with chemotherapy, with an anticipated preliminary completion date in…
-
Genmab CEO Cites China’s Biotech as a ‘Mind-Boggling’ Source of Innovation
•
Jan van de Winkel, CEO of Denmark-based biotech Genmab (NASDAQ: GMAB), has expressed optimism about the potential of China’s biotech industry to drive innovation for multinational corporations (MNCs). This sentiment comes in the wake of Genmab’s significant foray into the Chinese market with the acquisition of Sino-US antibody-drug conjugate (ADC)…
-
ProfoundBio Receives FDA Approval for PRO1184, Appoints New CMO
•
China-based macromolecular targeted therapy developer ProfoundBio (Suzhou) Co., Ltd announced that it has received clinical trial approval from the US Food and Drug Administration (FDA) for its antibody drug conjugate (ADC) PRO1184 in advanced tumors. The announcement was made alongside the appointment of Dr. Naomi Hunder as the company’s chief…
